Neuropharmacology of N,N-dimethyltryptamine
- PMID: 27126737
- PMCID: PMC5048497
- DOI: 10.1016/j.brainresbull.2016.04.016
Neuropharmacology of N,N-dimethyltryptamine
Abstract
N,N-dimethyltryptamine (DMT) is an indole alkaloid widely found in plants and animals. It is best known for producing brief and intense psychedelic effects when ingested. Increasing evidence suggests that endogenous DMT plays important roles for a number of processes in the periphery and central nervous system, and may act as a neurotransmitter. This paper reviews the current literature of both the recreational use of DMT and its potential roles as an endogenous neurotransmitter. Pharmacokinetics, mechanisms of action in the periphery and central nervous system, clinical uses and adverse effects are also reviewed. DMT appears to have limited neurotoxicity and other adverse effects except for intense cardiovascular effects when administered intravenously in large doses. Because of its role in nervous system signaling, DMT may be a useful experimental tool in exploring how the brain works, and may also be a useful clinical tool for treatment of anxiety and psychosis.
Keywords: Hallucinogen; N,N-dimethyltryptamine; Neurotransmitter; Psychiatric disorder.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.J Psychopharmacol. 2014 Jan;28(1):49-54. doi: 10.1177/0269881113513852. Epub 2013 Nov 27. J Psychopharmacol. 2014. PMID: 24284475
-
A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.J Neural Transm (Vienna). 2013 Sep;120(9):1295-303. doi: 10.1007/s00702-013-1024-y. Epub 2013 Apr 26. J Neural Transm (Vienna). 2013. PMID: 23619992 Review.
-
Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.J Psychopharmacol. 2007 May;21(3):312-20. doi: 10.1177/0269881107077734. J Psychopharmacol. 2007. PMID: 17591658 Clinical Trial.
-
Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).ACS Chem Neurosci. 2018 Oct 17;9(10):2344-2357. doi: 10.1021/acschemneuro.8b00101. Epub 2018 Jul 23. ACS Chem Neurosci. 2018. PMID: 30036036 Review.
-
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants.Transl Psychiatry. 2023 May 23;13(1):172. doi: 10.1038/s41398-023-02477-4. Transl Psychiatry. 2023. PMID: 37221177 Free PMC article. Clinical Trial.
Cited by
-
Brain substates induced by DMT relate to sympathetic output and meaningfulness of the experience.bioRxiv [Preprint]. 2024 Apr 17:2024.02.14.580356. doi: 10.1101/2024.02.14.580356. bioRxiv. 2024. PMID: 38464275 Free PMC article. Preprint.
-
Effects of hallucinogenic drugs on the human heart.Front Pharmacol. 2024 Feb 2;15:1334218. doi: 10.3389/fphar.2024.1334218. eCollection 2024. Front Pharmacol. 2024. PMID: 38370480 Free PMC article. Review.
-
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Curr Neuropharmacol. 2024;22(4):636-735. doi: 10.2174/1570159X22666231027111147. Curr Neuropharmacol. 2024. PMID: 38284341 Free PMC article. Review.
-
Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.Front Psychiatry. 2024 Jan 11;14:1305796. doi: 10.3389/fpsyt.2023.1305796. eCollection 2023. Front Psychiatry. 2024. PMID: 38274414 Free PMC article.
-
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects.Front Psychiatry. 2024 Jan 8;14:1302559. doi: 10.3389/fpsyt.2023.1302559. eCollection 2023. Front Psychiatry. 2024. PMID: 38264636 Free PMC article.
References
-
- Aghajanian GK, Foote WE, Sheard MH. Action of psychotogenic drugs on single midbrain raphe neurons. J Pharmacol Exp Ther. 1970;171:178–187. - PubMed
-
- Aghajanian GK, Marek GJ. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacol. 1997;36:589–599. - PubMed
-
- Aghajanian GK, Marek GJ. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 1999a;825:161–171. - PubMed
-
- Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacol. 1999b;21:16–23. - PubMed
-
- Agurell S, Holmstedt B, Lindgren JE, Schultes RE. Identification of two new p-carboline alkaloids in South American hallucinogenic plants. Biochem Pharmacol. 1968;17:2487–2488. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources